We are a fast-growing, international biotech company committed to improving the lives of people with our differentiated antibody medicines.
We have committed to a new vision for our future that by 2030, our knock-your-socks-off “KYSO” antibody medicines are fundamentally transforming the lives of people with cancer and other serious diseases.
We have a proven track record in discovery and development, which we are now augmenting with commercial capabilities as we transition into an integrated biotech with the aspiration to bring medicines to patients.
Founded in Copenhagen, Denmark in 1999, Genmab A/S’s ordinary shares are listed on the Nasdaq Copenhagen A/S under the ticker symbol GMAB and are traded as part of the OMXC25. Genmab’s American Depositary Shares issued under the ADR Program are listed in the U.S. on the Nasdaq Global Select Market under the ticker symbol GMAB, and the shares are included in the NASDAQ Biotechnology Index (Nasdaq: NBI).
Register your email to receive electronic shareholder communications from Genmab including the calling of Genmab’s Annual General Meeting. Log on to the InvestorPortal, add your email under “My profile” and select your communication preferences.